Jeanmarie Guenot has been a business administrator for over 20 years and at present serves as president of Amphivena Therapeutics Inc. Never one to be satisfied with only one challenge at a time she works in commercial development, project management, venture capital, and stays involved with research and development in the pharmaceutical industry.
JeanMarie also has a company, Guenot LLC, that offers several high-level consulting services to biotechnology and pharmaceutical firms. She is well-versed and experienced in areas like licensing, finance, mergers and acquisition, and commercial planning.
Ms. Guenot is impressively well-educated, which CrunchBase shows. She earned an MBA from the Wharton School, University of Pennsylvania, and a Ph.D. from the University of California, San Francisco. Her resume includes training in physical and medicinal chemistry, designing specialized drugs, quantum mechanical and semi-empirical methods, and just to round things out, protein structure and prediction.
Jeanmarie Guenot began her blended career of business and science at Hoffman-La Roche (science) in preclinical research and development where she was identifying and developing drugs used to fight serious illnesses including those in the field of oncology.
On the business side, she was hired by Atlas Ventures to manage capital investments. In her capacity at Atlas, she focused on creating and incubating life science companies.
Between her time at these two firms and the moment she began leading the way at Amphivena, Jeanmarie founded and ran a company, engaged in high-level negotiating for other businesses, funded several startups and developed or co-developed effective drugs used to combat autoimmune diseases.
She is well-known in the industry and has a reputation for integrity, professionalism, hard work, and successfully leading large organizations.
Jeanmarie uses her scientific and business management experience at Amphivena Therapeutics to develop innovative treatments for hematological malignancies.
The firm opened for business in July 2013, with the mission to completely get rid of blood cancers like acute myeloid leukemia with a new therapy that puts the patient’s immune system to work destroying cancerous cells.